General
Preferred name
carnosine
Synonyms
Polaprezinc ()
Karnozin ()
beta-Alanyl-L-histidine ()
L-CARNOSINE ()
Zinc L-carnosine ()
Promac ()
Z-103 ()
Z 103 ()
L-Carnosine-d4 ()
P&D ID
PD001527
CAS
305-84-0
107667-60-7
2714339-90-7
Tags
drug candidate
natural product
available
Drug indication
Discovery agent
Drug Status
experimental
investigational
Max Phase
Phase 2
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
MOA Polaprezinc increases the expression of various antioxidant enzymes, including superoxide dismutase 1 (SOD-1), SOD-2, heme oxygenase-1 (HO-1), glutathione S-transferase (GST), glutathione peroxidase (GSH-px), peroxidredoxin-1 (PRDX1; PRXI) and PRXD5 (PRXV). ; ; This process occurs in the gastric mucosa, defending mucosal cells against reactive oxygen species. This drug inhibits the activity of the transcription factor nuclear factor-kappaB (NF-kB) and decreases the expression of various inflammatory cytokines, including interleukin (IL) 1beta, IL-6, IL-8, and tumor necrosis factor alpha (TNF-a). ; ; Polaprezinc also promotes the expression of numerous growth factors, including as platelet-derived growth factor-B (PDGF-B), vascular endothelial growth factor (VEGF), and nerve growth factor (NGF), in addition to various heat shock proteins (HSPs), including HSP90, HSP70, HSP60, HSP47, HSP27, and HSP10. This process promotes tissue growth and protects against damage the gastric mucosa [L1308].
ROE Intestinal absorption of the drug was examined using 14C- and 65Zn-labeled compounds. Polaprezinc metabolizes into its components, L-carnosine and zinc, during intestinal absorption. It was found that the excretion rates after one administration using 14C-labeled L-CAZ to rats were 4.1% in urine, 13.3% in feces, and 38.8% in exhalation. The study using 65Zn-labeled Paleprozinc were 0.3% in urine and 85.0% in the feces. The absorption rate of zinc is estimated to be approximately 11% [L1309].;
ABSORPTION Intestinal absorption of L-CAZ was studied in rats by Sano et al. [L1309] using 14C- and 65Zn-labeled compounds. They suggested that L-CAZ dissociates to its components, L-carnosine and zinc, during intestinal absorption [L1309]. ;
DESCRIPTION Polaprezinc is a chelate composed of zinc and L-carnosine, which exhibits gastroprotective, antioxidant, anti-ulcer and anti-inflammatory effects. It is approved in Japan for the treatment of gastric ulcers.
Nutritional supplement in health care products. (BOC Sciences Bioactive Compounds)
Compound Sets
18
BOC Sciences Bioactive Compounds
polaprezinc-cas-107667-60-7-item-54044
Cayman Chemical Bioactives
26781
ChEMBL Drugs
CHEMBL242948
Concise Guide to Pharmacology 2017/18
4559
Concise Guide to Pharmacology 2019/20
4559
Concise Guide to Pharmacology 2021/22
4559
Concise Guide to Pharmacology 2023/24
4559
Drug Repurposing Hub
DrugBank
DB11695
DB09221
DrugMAP
DMFYCB4
Guide to Pharmacology
4559
MedChem Express Bioactive Compound Library
HY-W013494
Natural product-based probes and drugs
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
l-carnosine
TargetMol Bioactive Compound Library
T4732
The Spectrum Collection
External IDs
72
Properties
(calculated by RDKit )
Molecular Weight
226.11
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
4
Rotatable Bonds
6
Ring Count
1
Aromatic Ring Count
1
cLogP
-1.13
TPSA
121.1
Fraction CSP3
0.44
Chiral centers
1.0
Largest ring
5.0
QED
0.49
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
oxidation-reduction
Immunology/Inflammation
Metabolic Enzyme/Protease
Target
antioxidant
Endogenous Metabolite
MOA
Antioxidant
antiglycating agent
Biosynthetic Origin
Other (Amino Acid)
Therapeutic Indication
Antiulcer
Source data